Drug Database
AN

antithrombin III

✓ Approved

GC Biopharma · SERPINC1 · 细胞治疗

什么是 antithrombin III?

antithrombin III 是一种细胞治疗,由GC Biopharma研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。

药物档案

公司GC Biopharma
药物类别细胞治疗
分子靶点SERPINC1
给药途径Injectable (Others), Intravenous (IV)
状态Approved

作用机制

分子靶点

antithrombin III 作用于 1 个分子靶点:

SERPINC1serpin family C member 1 (ATIII, AT3D)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

antithrombin III 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Congenital, familial and genetic disordersAntithrombin III deficiency✓ Approved

相关研究文献

PubMedThrombosis journal2026-11-19

Concentration-dependent and platform-specific interference of argatroban and bivalirudin in routine coagulation assays.

Yan Jinghai J, Chen Wanjun W, Chen Weidong W, Yang Yongqiang Y et al.

Argatroban and bivalirudin may interfere with routine coagulation and antithrombin assays through direct thrombin inhibition. However, the magnitude of interference differs across analytical platforms owing to distinct assay principles and reagent formulations. This study aimed to characterize the specific impacts of argatroban and bivalirudin on results of routine coagulation and antithrombin tests on three widely utilized coagulation analytical platforms. Pooled normal human plasma was spiked with clinically relevant concentrations of argatroban (0-2.0 µg/mL) or bivalirudin (0-20 mg/L). Antithrombin (AT) activity, prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), and Clauss fibrinogen (FIB) were measured simultaneously on all three analytical platforms. Corresponding antigen concentrations of AT and ClaussFIB were quantified via immunoassays to discriminate analytical interference from genuine biological alterations. On Stago and Sysmex platforms, AT activity increased concentration‑dependently with both DTIs, whereas no significant change was observed on Werfen. Fibrinogen levels decreased markedly with argatroban only on Werfen, and with bivalirudin across all three platforms. PT, APTT, and TT were prolonged dose‑dependently on all platforms, though TT frequently exceeded the detection limit at low DTI concentrations. Inter‑platform agreement assessed by intraclass correlation coefficients was poor to moderate for most parameters. Antigen levels remained unchanged, confirming that the observed discrepancies were due to analytical interference. Argatroban and bivalirudin produce significant platform-dependent interference in coagulation testing, particularly in thrombin-based fibrinogen and AT activity assays. Such interference may lead to falsely decreased fibrinogen activity and falsely elevated AT activity. Platform-specific validation and confirmatory testing are essential for accurate interpretation of coagulation results during direct thrombin inhibitor therapy.

PMID 43053079
阅读全文 →
PubMedFuture science OA2026-11-19

Efficacy and safety of romiplostim in refractory aplastic anaemia: a plain language summary of phase II/III, multicentre, open-label study.

Jang Jun Ho JH, Mitani Kinuko K, Yoshizawa Shigeru S, Gamou Masaru M et al.

PMID 43053733
阅读全文 →
PubMedJournal of hand therapy : official journal of the American Society of Hand Therapists2026-11-19

Barriers to post-stroke hand function recovery: A Delphi-based expert consensus on contributing factors and rehabilitation strategies.

Tiwari Prachi P, Mani Suresh S, Agarwal Nidhi N, Kohli Sunil S et al.

Post-stroke hand function impairment affects 60-70% of survivors at six months, persisting despite abundant guidelines that rarely differentiate protocols by Brunnstrom recovery stages-creating a critical gap in stage-specific guidance for Stage III challenges like synergistic overflow. To achieve expert consensus on primary barriers, neurophysiological mechanisms, and most effective rehabilitation strategies for hand function recovery in stroke survivors specifically at Brunnstrom Stage III. Modified three-round e-Delphi consensus study. Purposive sampling recruited 15 Indian neurorehabilitation experts (8 academicians with ≥10 years teaching/3 recent publications, 7 clinicians with ≥5 years experience/≥20% stroke caseload) from 50 invitees (30% response rate). Round 1 used three open-ended questions yielding 42 themes refined to 28 Likert-scale items (Supplementary Files S1-S2). Rounds 2-3 rated agreement (≥70%=strong consensus); thematic analysis and descriptive statistics (mean %, 95% CI) applied. Finger extensor weakness achieved highest consensus as primary barrier (81.2% mean agreement, 95% CI ±5.6%). Motor Relearning Program (MRP: 80.5%, ±4.9%) and Neurodevelopmental Therapy (NDT: 76.4%, ±5.4%) emerged as top strategies. Brunnstrom Stage III challenges (synergistic overflow, movement initiation: 67.2%, ±6.5%) reached moderate consensus; low-consensus items included robotics (38.7%) due to resource constraints. Muscle weakness-particularly finger extensors-dominates Stage III hand recovery barriers; MRP and NDT offer highest-priority interventions. Clinicians should prioritize stage-specific strengthening protocols over generic approaches, informing tailored guidelines for resource-limited settings. - Ethical approval for the study was granted by the Institutional Ethics Committee (Approval No. LPU/SOP/50/210527/15619/002).

PMID 43053507
阅读全文 →
PubMedJournal of cardiothoracic surgery2026-11-19

Aortic arch types and arch anomalies in patients undergoing carotid endarterectomy: a retrospective single-center analysis and comparison with population prevalences.

Beyaz Metin Onur MO, Kaya Sefer S

Aortic arch anatomy affects the feasibility and safety of endovascular carotid interventions. Data on the distribution of aortic arch types and branching anomalies in patients undergoing carotid endarterectomy (CEA), particularly from the Eastern Mediterranean region, remain limited. This study aimed to determine the prevalence of aortic arch types (I-III) and arch anomalies in a CEA cohort and compare these findings with population prevalences. A retrospective, single-center, observational study was conducted on 532 consecutive patients who underwent unilateral CEA due to carotid stenosis at Hatay Mustafa Kemal University Hospital between January 2020 and December 2025. Preoperative computed tomography angiography images were reviewed to classify arch type and identify branching anomalies. Descriptive statistics were calculated with Wilson 95% confidence intervals. Observed prevalence rates were compared with published reference values using one-sample proportion tests and chi-square goodness-of-fit analysis. Associations between arch type and clinical variables were evaluated using chi-square and Kruskal-Wallis tests. Logistic regression identified independent predictors of arch anomalies. The cohort (mean age 70.6 ± 8.6 years; 66.9% male; 57.9% symptomatic) showed the following arch type distribution: Type I 49.4%, Type II 34.6%, and Type III 16.0%. Half of the patients (50.6%) had complex arch anatomy (Type II-III). The overall distribution differed from that reported by Zhang et al. (χ² = 44.3, p < 0.001), with fewer Type III aortic arches. Aortic arch anomalies were identified in 19.7%: bovine arch in 16.2%, left vertebral artery arising from the arch in 2.8%, aberrant right subclavian artery in 1.1%, and right aortic arch in 0.2%. No demographic or clinical variable independently predicted anomaly presence (all p > 0.2). These disparities likely reflect ethnic anatomical variation between Eastern Mediterranean and East Asian populations. In this Eastern Mediterranean CEA cohort, Type III arch was less frequent than in previously reported series, and arch anomalies were present in approximately one-fifth of patients. The arch type distribution was independent of clinical risk factors, supporting the view that arch anatomy reflects intrinsic variation rather than atherosclerotic burden. These findings may help inform pre-procedural planning when endovascular alternatives to CEA are considered.

PMID 43053176
阅读全文 →
PubMedBMC women's health2026-11-19

Performance of a DNA methylation marker panel in cervical samples from women with abnormal cytology findings.

Zeiser Ilona I, Schubert Katja K, Hippe Juliane J, Hansel Alfred A et al.

Reliable triage methods are essential in cervical cancer screening to avoid overtreatment. DNA methylation markers offer an objective molecular readout with potential to keep false-positive rates low. We evaluated the GynTect® DNA methylation assay as a triage marker in cervical samples from women with abnormal cytology, in comparison with the p16/Ki-67 Dual Stain test CINtec Plus®. Surplus liquid-based cytology samples from 1,000 women with cytology ≥ PAP III (Low-Grade Squamous Intraepithelial Lesion = LSIL, or worse) were tested with GynTect® (markers: ASTN1, DLX1, ITGA4, RXFP3, SOX17, ZNF671). cobas® HPV and p16/Ki-67 Dual Stain (CINtec Plus®) results were available for all samples; histopathology was available for a subset of 601 samples. Positivity rates with 95% confidence intervals were calculated using the Wilson score method. Overall GynTect positivity was 27.7% versus 88.3% for p16/Ki-67 Dual Stain. Methylation positivity correlated with cytological severity: 17.0% in LSIL, 30.2% in moderate High-​Grade Squamous Intraepithelial Lesion HSIL, and 65.0% in the PAP IV group (high-grade SIL/AIS and HSIL suspicious for invasion). Among HPV16/18-positive samples, 38.4% were GynTect-positive versus 94.8% p16/Ki-67 Dual Stain-positive. By histopathology, GynTect positivity was 15.0% (CIN I), 27.0% (CIN II), and 56.5% (CIN III); all four cancer cases were GynTect- and p16/Ki-67 Dual Stain​-positive. Of 191 GynTect-positive cases with histopathology, 73% had CIN II or CIN III. GynTect positivity (27.7%) was significantly lower than p16/Ki-67 Dual Stain positivity (88.3%), with a statistically significant monotonic trend across increasing cytological severity (Cochran-Armitage trend test, p < 0.001) and histopathological categories (p < 0.001). All four histologically confirmed carcinomas were GynTect-positive. These findings are consistent with a potential role for GynTect in selective triage after abnormal cytology, with lower positivity rates suggesting higher selectivity for high-grade disease compared with p16/Ki-67 Dual Stain. Prospective validation in primary HPV-screening triage populations is required to determine whether this translates into clinical benefit.

PMID 43052966
阅读全文 →
PubMedJournal of prosthodontics : official journal of the American College of Prosthodontists2026-11-19

Basic concepts of rotational path removable partial denture: A narrative review and case report.

Sones Amerian D AD, Kienzle Kason K, Batagower Jordan J, Bergamini Marco M et al.

The rotational path removable partial denture (RPRPD) design is a viable treatment approach for the esthetic and functional rehabilitation of Kennedy's Classification III and IV partially edentulous patients. The purpose of this article is to review indications, contraindications, advantages, and disadvantages of the basic concepts of RPRPD. This part reviews the philosophy of the basic concept, working from analog to a digital workflow. Two clinical cases for RPRPD are described in detail.

PMID 43053639
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多antithrombin III